Skip to main content

Table 3 Tested patient characteristics (n = 646)

From: Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

Age

 Median, yrs

64

 Range, yrs

6–93

Gender, n (%)

 Female

359 (55%)

 Male

298 (45%)

Stage, n (%)

 Stage I

9 (1.4%)

 Stage II

11 (1.7%)

 Stage III

54 (8%)

 Stage IV

506 (77%)

 Unknown

77 (12%)

Tumor Type, n (%)

 Bladder

4 (0.61%)

 Brain

15 (2.3%)

 Breast

34 (5%)

 Cervical

4 (0.61%)

 Colorectal

68 (10%)

 Endocrine

3 (0.46%)

 Endometrial

25 (3.8%)

 Esophageal

13 (2%)

 Eye

1 (0.2%)

 Female Genital

1 (0.2%)

 Gallbladder

3 (0.5%)

 Head and Neck

4 (0.6%)

 Kidney and Renal Pelvis

10 (1.5%)

 Liver and Bile Duct

1 (0.15%)

 Lung

205 (31%)

 Melanoma

51 (8%)

 Mesothelioma

4 (0.6%)

 Neuroendocrine Tumors

14 (2.1%)

 Non-Melanoma Skin

2 (0.3%)

 Ovarian

44 (7%)

 Pancreatic

9 (1.4%)

 Prostate

34 (5%)

 Sarcoma

87 (13%)

 Small Intestine

3 (0.5%)

 Stomach

3 (0.5%)

 Testicular

1 (0.2%)

 Thymic

3 (0.5%)

 Thyroid

4 (0.6%)

 Unknown Primary

7 (1%)

Prior systemic treatment

 Unknown

4 (0.6%)

 0

156 (24%)

 1+

497 (76%)